<DOC>
	<DOCNO>NCT01458548</DOCNO>
	<brief_summary>Post-transplantation lymphoproliferative disorder ( PTLD ) develop one ten per cent transplant recipients EBV-associated . To improve long-term efficacy rituximab monotherapy avoid toxicity CHOP see first-line treatment , investigator initiate international multicentre phase II trial test whether subsequent application rituximab four course three-weekly CHOP would improve outcome patient PTLD : PTLD-1 , sequential treatment ( ST ) .</brief_summary>
	<brief_title>Sequential Treatment CD20-positive Posttransplant Lymphoproliferative Disorder ( PTLD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>PTLD without EBV association , confirm biopsy resection Measurable disease &gt; 2 cm diameter and/or bone marrow involvement Patients undergone heart , lung , liver , kidney , pancreas , small intestine transplantation combination organ transplantation mention Karnofsky scale &gt; 50 % ECOG ≤ 3 Reduction immunosuppression without antiviral therapy A complete surgical extirpation tumor perform A radiation therapy perform Effective contraception woman childbearing age Patient 's write informed consent write consent data collection Patients &gt; 18 year ( ≥ 15 year parental agreement ) Life expectancy le 6 week Karnofskyscale &lt; 50 % ECOG =3 Treatment rituximab Known allergic reaction foreign protein Concomitant disease , exclude administration therapy outline study protocol noncompensated heart failure Dilatative cardiomyopathy Myocardial infarction last 6 month Severe noncompensated hypertension Severe noncompensated diabetes mellitus Renal insufficiency ( creatinine 3fold upper normal value ) , related lymphoma . Hepatic insufficiency transaminase value great 3fold normal value and/or bilirubin level &gt; 3.0 mg/dl , relate lymphoma Clinical sign cerebral dysfunction Women lactation period , pregnant childbearing potential use reliable contraceptive method Involvement central nervous system disease Severe psychiatric disease Known HIV positive Missing write informed consent patient</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>1st-line therapy</keyword>
	<keyword>single agent rituximab</keyword>
	<keyword>CHOP</keyword>
	<keyword>PTLD</keyword>
</DOC>